

# Tyng-Yuan Jang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8598857/publications.pdf>

Version: 2024-02-01

35  
papers

269  
citations

1307594

7  
h-index

1058476

14  
g-index

35  
all docs

35  
docs citations

35  
times ranked

388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. American Journal of Gastroenterology, 2020, 115, 271-280.	0.4	72
2	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS ONE, 2017, 12, e0178883.	2.5	18
3	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Scientific Reports, 2021, 11, 8184.	3.3	17
4	Association of hyperuricemia with disease severity in chronic hepatitis C patients. PLoS ONE, 2018, 13, e0207043.	2.5	13
5	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Scientific Reports, 2021, 11, 8554.	3.3	11
6	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver International, 2022, 42, 59-68.	3.9	10
7	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World Journal of Gastroenterology, 2022, 28, 263-274.	3.3	10
8	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clinical and Molecular Hepatology, 2021, 27, 186-196.	8.9	9
9	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine (United States), 2019, 98, e15066.	1.0	8
10	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1886-1892.	2.8	8
11	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Journal of the Formosan Medical Association, 2021, 120, 303-310.	1.7	8
12	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 473-481.	2.8	7
13	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Medicine, 2022, 11, 104-116.	2.8	7
14	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. Journal of the Formosan Medical Association, 2022, 121, 1767-1772.	1.7	7
15	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. Journal of the Chinese Medical Association, 2021, 84, 255-260.	1.4	6
16	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World Journal of Gastroenterology, 2022, 28, 140-153.	3.3	6
17	Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan. Journal of the Formosan Medical Association, 2022, , .	1.7	6
18	Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient. Medicine (United States), 2016, 95, e5304.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PLoS ONE, 2021, 16, e0245479.	2.5	5
20	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. Journal of Viral Hepatitis, 2021, 28, 719-727.	2.0	5
21	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS ONE, 2020, 15, e0242601.	2.5	5
22	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). Hepatology International, 2022, 16, 59-67.	4.2	5
23	Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. BMJ Open Gastroenterology, 2020, 7, e000543.	2.7	3
24	Suppression of hepatitis C virus replication during COVID-19 infection. Kaohsiung Journal of Medical Sciences, 2022, 38, 394-395.	1.9	3
25	Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes. Kaohsiung Journal of Medical Sciences, 2022, 38, 897-906.	1.9	3
26	Hepatocellular carcinoma metastatic to kidney mimicking renal cell carcinoma. Kaohsiung Journal of Medical Sciences, 2017, 33, 161-162.	1.9	2
27	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2261-2269.	2.8	2
28	Serum Wisteria floribunda <scp>agglutininâ€positive Macâ€2â€binding</scp> protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung Journal of Medical Sciences, 2022, 38, 261-267.	1.9	2
29	Itemization difference of patient-reported outcome in patients with chronic liver disease. PLoS ONE, 2022, 17, e0264348.	2.5	2
30	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuán, a hyperendemic area of southern Taiwan. Kaohsiung Journal of Medical Sciences, 2022, , .	1.9	2
31	Why cannot Taiwan be COVID-19 free?. Journal of the Formosan Medical Association, 2022, 121, 2365-2366.	1.7	2
32	Hypopharyngeal and Laryngeal Lesions in a Patient with Chickenpox. Ear, Nose and Throat Journal, 2020, 100, 014556132093231.	0.8	0
33	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A communityâ€based cohort study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3239-3246.	2.8	0
34	The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. Pathogens, 2021, 10, 1227.	2.8	0
35	The compound annual growth rate of the fibrosisâ€4 index in chronic hepatitis B patients. Kaohsiung Journal of Medical Sciences, 2022, , .	1.9	0